Kalita Dipti, Rastogi Ruchi, Bhatnagar Gunmala, Medhi Kunjahari, Pandey Sanjay K
Laboratory Medicine, Histopathology and Cytopathology, Batra Hospital and Medical Research Centre, New Delhi, IND.
Laboratory Medicine, Histopathology and Cytopathology, Batra Hospital and Medical Research centre, New Delhi, IND.
Cureus. 2024 Jan 10;16(1):e52069. doi: 10.7759/cureus.52069. eCollection 2024 Jan.
Inflammatory myofibroblastic tumors (IMTs) are rare spindle cell tumors clinically, morphologically, and genetically heterogeneous, mimicking many other reactive and neoplastic lesions and creating great diagnostic problems. Although it is generally characterized by oncogene-derived proliferation of myofibroblasts in a background of polyclonal inflammatory cell infiltrates, morphological variations do occur requiring immunohistochemistry and molecular genetics to confirm the diagnosis. It encompasses a wide age range, and locations, mostly said to be of intermediate grade having a low risk of recurrence and metastasis. However, its biological behavior and course are variable and unpredictable. Here, we report a case of thoracic IMT in a 32-year-old adult female presenting with a history of fever, cough, and chest pain associated with neutrophilic leukocytosis. Radiological investigations revealed a large mass in the thoracic region with possibilities of hydatid cyst and neurogenic tumor. Initial core needle biopsy specimen and subsequent local resection specimen revealed the diagnosis of IMT on histopathology and immunohistochemistry, having conventional morphology with expression of Anaplastic lymphoma kinase (ALK) protein. The patient developed rapid local recurrence and was started with first-generation ALK inhibitor Crizotinib. After a brief period of response, she developed vertebral and brain metastasis within a short span of time and was switched to a third-generation ALK inhibitor, Lorlatinib. The patient is on regular follow-up, has stable disease, and maintains a good quality of life after two years of diagnosis.
炎性肌纤维母细胞瘤(IMTs)是一种罕见的梭形细胞肿瘤,在临床、形态学和遗传学上具有异质性,可模仿许多其他反应性和肿瘤性病变,从而产生巨大的诊断问题。尽管其通常特征为在多克隆炎性细胞浸润背景下由癌基因驱动的肌成纤维细胞增殖,但形态学变异确实存在,这就需要免疫组织化学和分子遗传学来确诊。它涵盖广泛的年龄范围和部位,大多被认为是中级别的,复发和转移风险较低。然而,其生物学行为和病程是可变且不可预测的。在此,我们报告一例32岁成年女性的胸段IMT病例,该患者有发热、咳嗽和胸痛病史,伴有中性粒细胞增多。影像学检查显示胸段有一个大肿块,可能是包虫囊肿或神经源性肿瘤。最初的粗针活检标本及随后的局部切除标本经组织病理学和免疫组织化学检查确诊为IMT,具有典型形态且间变性淋巴瘤激酶(ALK)蛋白呈阳性表达。患者出现快速局部复发,开始使用第一代ALK抑制剂克唑替尼治疗。经过短暂的缓解期后,她在短时间内出现椎体和脑转移,随后改用第三代ALK抑制剂劳拉替尼。患者定期随访,病情稳定,确诊两年后生活质量良好。